Tolerance and efficacy of slow release octreotide in idiopathic pulmonary fibrosis. The FIBROSAND study
J. Chapron, Q. Dornic, M. P. Debray, M. Brauner, R. Lebtahi, P. Delaval, D. Israel-Biet, J. Lacronique, I. Monnet, M. Reynaud-Gaubert, A. Tazi, D. Valeyre, B. Wallaert, E. Bergot, F. Mentré, X. Duval, M. Dehoux, B. Crestani (Paris, Bobigny, Rennes, Créteil, Marseille, Lille, Caen, France)
Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Chapron, Q. Dornic, M. P. Debray, M. Brauner, R. Lebtahi, P. Delaval, D. Israel-Biet, J. Lacronique, I. Monnet, M. Reynaud-Gaubert, A. Tazi, D. Valeyre, B. Wallaert, E. Bergot, F. Mentré, X. Duval, M. Dehoux, B. Crestani (Paris, Bobigny, Rennes, Créteil, Marseille, Lille, Caen, France). Tolerance and efficacy of slow release octreotide in idiopathic pulmonary fibrosis. The FIBROSAND study. Eur Respir J 2010; 36: Suppl. 54, 392
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: